# $ZER Catalyst Posts & Social Intelligence Recap — April 13, 2026

> **Asset:** $ZER  
> **Date:** 2026-04-13 (April 13, 2026)  
> **Canonical URL:** https://cryptitalk.com/tokens/zer/2026-04-13  
> **Token Profile:** https://cryptitalk.com/tokens/zer.md  
> **Market Rankings:** https://cryptitalk.com/rankings.md  

---



## Curated Viral Posts & Community Evidence


### Post #1 by @CoinMarketCap:BSCNews
> **Author:** ([@CoinMarketCap:BSCNews](https://x.com/CoinMarketCap:BSCNews))  
> **Metrics:** 0 likes · 0 retweets · 0 comments  

> **Posted:** 2026-04-13T12:35:09.459416+00:00  


> **Source Link:** [https://coinmarketcap.com/community/articles/69dce09e5002f14e8f531fa4/](https://coinmarketcap.com/community/articles/69dce09e5002f14e8f531fa4/)  


> 
> "A Very Bad Sign? Hong Kong Delays Stablecoin Licenses


Hong Kong has not issued a single stablecoin license despite senior officials publicly targeting March 2026 for the first batch of approvals. The HKMA's official Register of Licensed Stableco"


### Post #2 by @CoinMarketCap:BSCNews
> **Author:** ([@CoinMarketCap:BSCNews](https://x.com/CoinMarketCap:BSCNews))  
> **Metrics:** 0 likes · 0 retweets · 0 comments  

> **Posted:** 2026-04-13T12:35:09.459472+00:00  


> **Source Link:** [https://coinmarketcap.com/community/articles/69dce09e1f815c52ae903cf1/](https://coinmarketcap.com/community/articles/69dce09e1f815c52ae903cf1/)  


> 
> "Kaspa's Toccata Hard Fork: Covenants, ZK Opcodes, And A New June Target


Kaspa's upcoming Toccata hard fork will add two new programmability paths to the network: native L1 covenant programming and based zero-knowledge (zk) application infrastructure, with mainnet"


### Post #3 by @CoinMarketCap:blockonomi
> **Author:** ([@CoinMarketCap:blockonomi](https://x.com/CoinMarketCap:blockonomi))  
> **Metrics:** 0 likes · 0 retweets · 0 comments  

> **Posted:** 2026-04-13T16:45:02.333194+00:00  


> **Source Link:** [https://coinmarketcap.com/community/articles/69dd1b351f815c52ae903e2f/](https://coinmarketcap.com/community/articles/69dd1b351f815c52ae903e2f/)  


> 
> "Allogene Therapeutics (ALLO) Stock Soars 41% Following Breakthrough CAR T-Cell Trial Results


Key Highlights ALPHA3 trial demonstrated 58.3% MRD negativity in cema-cel patients compared to just 16.7% in the observation group Zero instances of cytokine release syndrome or neurotoxicity"




---

*Generated by Context Pilot Social Intelligence Engine.*